GET DAILY SIGNALSAdagio Medical Holdings (ADGM) Shares Fall -31% Over 30 Days on Reverse Split and Dilution
Key Takeaways
- Adagio Medical Holdings (ADGM) shares have declined roughly 31% over the trailing 30 days, extending a prolonged downtrend for the micro-cap medical device developer.
- The recent decline has been driven by a 1-for-30 reverse stock split, continued dilution from convertible-note conversions, and ongoing Nasdaq minimum bid price compliance concerns.
- Over the trailing quarter, the stock has lost roughly 85–90% of its value on a split-adjusted basis, reflecting persistent financing and cash-burn pressures.
- Adagio develops ultra-low temperature cryoablation technologies for cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia.
- Management has reduced headcount and is exploring strategic alternatives while working to secure additional funding.
- Investors seeking deeper analysis can explore dedicated Price Targets, Earnings, and Forecast pages for additional context on the company's outlook.
Company Overview for Adagio Medical Holdings (ADGM)
Adagio Medical Holdings, Inc. is a medical technology company headquartered in Laguna Hills, California. The company develops and commercializes ultra-low temperature cryoablation systems designed to treat cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio includes the iCLAS atrial ultra-low temperature cryoablation catheter and system, the vCLAS ventricular catheter, and Cryopulse pulsed field cryoablation catheters.
Founded in 2011, Adagio operates in the large electrophysiology market for catheter-based ablation. The company remains at a relatively early commercial stage with minimal revenue, and its shares trade at a micro-cap valuation. Investors follow the stock primarily for its clinical and regulatory progress in the cardiac ablation space, while also weighing its significant financing and balance-sheet risks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ADGM Stock Price Performance Over the Last 30 Days and Quarter
Over the trailing 30 days, ADGM shares have fallen approximately 31% on a split-adjusted basis, declining from a close near $2.67 to roughly $1.85 as of the most recent available session. This move extends a much longer decline rather than representing an isolated pullback.
The broader picture is more severe. Over the trailing quarter, the stock has shed roughly 85–90% of its value on a split-adjusted basis, sliding from double-digit levels in mid-September to under $2 by mid-November. The trend reflects a sustained deterioration driven by dilution, financing uncertainty, and a reverse stock split, rather than a single earnings catalyst.
Factors Behind the Recent 30-Day Decline in ADGM
The sharpest pressure over the last 30 days came from Adagio's capital structure and listing status. On October 23, 2026, stockholders approved a reverse stock split in a range of 1-for-10 to 1-for-500 at the board's discretion. The company subsequently announced a 1-for-30 reverse split effective November 6, 2026, with split-adjusted trading beginning November 9, 2026. The shares fell sharply in the session following the announcement, reflecting investor concerns about the company's financial distress.
Dilution has also weighed heavily on the stock. Adagio carries 13% senior secured convertible notes that convert at a discount to the market price, and the company has issued millions of new common shares as noteholders converted their positions. This conversion activity expands the share count and places persistent downward pressure on the share price. From what I see, this dynamic has been a consistent theme in recent trading sessions.
Compounding these issues, the company faces Nasdaq minimum bid price noncompliance, has reduced its workforce, and has disclosed that its board is exploring strategic alternatives. Third-quarter results were due in the second week of November 2026, keeping near-term financing and cash-burn questions in focus.
Quarterly Performance Drivers and Financial Position
The quarterly decline is rooted in a broader financing and liquidity crisis that has unfolded over several months. Adagio's stock fell below Nasdaq's $1.00 minimum bid price requirement in June 2026, triggering a compliance period and raising delisting risk. The company's efforts to address this — including the reverse split authorization — have not stabilized the share price.
Underlying the price action is a weak financial position. The company has reported minimal revenue, ongoing operating losses, negative equity, and rising debt. As of June 30, 2026, preliminary cash stood near $7.7 million, and management has implemented workforce reductions. These fundamentals, combined with repeated share issuance tied to convertible-note conversions, have fueled the multi-month slide.
Key Factors to Monitor for ADGM Outlook
Several factors are likely to shape Adagio's outlook in the months ahead. Nasdaq listing compliance remains a central concern, with the company facing deadlines tied to its minimum bid price status. Further conversions of its senior secured convertible notes could continue to dilute existing shareholders and pressure the share price.
Investors should also monitor the outcome of the company's strategic alternatives review, any new financing arrangements, and its cash runway relative to ongoing operating losses. On the clinical side, progress toward regulatory milestones such as FDA submissions and expanded investigational device approvals could influence sentiment, though these developments have so far been offset by balance-sheet risks. The information above is not investment advice, and investors should conduct their own due diligence before making decisions. I’m watching this closely for any updates on the compliance front.
AI-Powered Trading Insights
In my research process, I often review Tickeron’s AI Trading Bots to see how automated strategies are positioning across volatile names like this one. These tools help compare different systematic approaches in one place, offering a useful complement to manual analysis for those focused on data-driven signals. The curated selection highlights top-performing bots across various timeframes and strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
ADGM's RSI Oscillator sits in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ADGM just turned positive on October 13, 2026. Looking at past instances where ADGM's MACD turned positive, the stock continued to rise in 18 of 19 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADGM advanced for three days, in 77 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ADGM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADGM as a result. In 37 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADGM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ADGM entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.473) is normal, around the industry mean (4.142). P/E Ratio (-0.047) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (60.976) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ADGM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADGM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement